An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Inclusion Criteria:

• Participants with a diagnosis of Crohn's disease (CD) confirmed by clinical,endoscopic and/or histological indices.

• Participants initiating risankizumab at the clinician's discretion as part of theirroutine clinical care.

• Participants prescribed risankizumab in accordance with the approved local label.

• Participants able to understand and communicate with the investigator and complywith the requirements of the study.

• Participants willing and able to provide authorization to use and disclose personalhealth information.

• Participants willing and able to participate in the collection of patient-reporteddata via cloud-based mobile application using a smart device (i.e., smartphone).

Exclusion Criteria:

• Females who are pregnant or breast feeding at baseline.

• Participants with any contraindication to risankizumab.

• Participants previously exposed to risankizumab.

• Participants currently participating in an interventional clinical trial.